Myeloid Therapeutics is developing a vaccine to address the COVID-19 pandemic

Planned ATAK™ Clinical Programs

Myeloid Therapeutics is planning multiple phase I clinical trials leveraging our proprietary ATAK™ platform to address the critical global viral crisis' in addition to important cancer indications

PRECLINICAL

PHASE 1

ATAK™ Cell Vaccine Studies

MT-201

Glioblastoma Vaccine

MT-201 ATAK™ Vaccine for glioblastoma. A collaboration between Duke and Myeloid Therapeutics.

Planned Phase 1: Single arm open-label ascending dose trial of myeloid vaccine in subjects with glioblastoma.

MT-202

Coronavirus Vaccine

MT-202 COVID-19 ATAK™ Vaccine for Long-Term T cell Immunity A collaboration between Duke and Myeloid Therapeutics & MaxCyte.

Planned Phase 1: Single arm open-label ascending dose trial of COVID-19 myeloid vaccine in healthy subjects.

ATAK™Cell

Cancer Studies

MT-101

Hematological Malignancies:

(T cell lymphomas)

MT-101 CD5-ATAK™ cell therapy for subjects with CD5 expressing T cell lymphomas

Planned Phase 1: Single arm open label ascending dose trial in subjects with CD5 expressing peripheral T cell lymphoma.

MT -102

Solid Tumors:

 

(HER2 expressing Gastric Cancer)

Cell Therapy for subjects with HER2 expressing malignancies.

Planned Phase 1: Single arm open-label ascending dose trial in subjects with HER2+ expressing gastric/GEJ malignancies.

© 2020,   Myeloid Therapeutics.  All rights reserved.

  • LinkedIn
  • Instagram
  • Twitter

GET IN

TOUCH

300 Technology Square, Suite 203  Cambridge, MA 02139